# Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

> **NCT04201873** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **BIOLOGICAL:** Dendritic Cell Tumor Cell Lysate Vaccine
- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Placebo Administration
- **DRUG:** Poly ICLC

## Key facts

- **NCT ID:** NCT04201873
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-08
- **Primary completion:** 2026-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-08-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04201873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04201873, "Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04201873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*